Neuroone Medical Technologies Corporation · NASDAQ:NMTC
Neuroone Medical Technologies — Investor Presentation (March 2024)
19 slides from Neuroone Medical Technologies's investor presentation, Mar 15, 2024
Slide 1: NeuroOne Medical Technologies Corporation March 2024
NASDAQ: NMTC NeuroOne ® Medical Technologies Corporation March 2024
Slide 2: Safe Harbor Statements
2 Safe Harbor Statements This presentation and any information included in this presentation are strictly confidential and should not be discussed outside of your organization. This presentation shall not constitute an offer to sell or a solicitation of an offer to buy any securities and shall not c
Slide 3: Investment Highlights
3 Investment Highlights Received FDA (510k) clearance for OneRF Ablation system in December 2023; for use with EVO sEEG ® electrodes to treat neurologic conditions Strategy to access the ablation market through additional partnerships leveraging the resources of commercial med tech companies or dire
Slide 4: Current/Future Applications and Indications for Electrode Technology
4 Current/Future Applications and Indications for Electrode Technology ▪ Currently used to detect, record and monitor neurological activity, stimulate tissue to regulate brain activity and provide pain relief ▪ Current industry indications: epilepsy, Parkinson’s Disease, chronic back pain, essential
Slide 5: Electrode Technology Value Proposition
5 Electrode Technology Value Proposition Highly Disruptive Thin - Film Technology with Superior Competitive Advantages Thin - Film & Flexibility Combination Device Cost & Manufacturin g ▪ Ultra High - definition technology increases signal clarity via lower impedance 1 (noise) ▪ May enable ablation
Slide 6: Diagnostic Thin-Film Depth Electrode Applications
6 Applications ▪ Epilepsy surgery ▪ Awake Brain Mapping C o m p e t i to r s P r o c e du r es ▪ Ad - Tech ▪ PMT ▪ Integra ▪ DIXI Market > $100M 1 Diagnostic Thin - Film Depth Electrode Can be used in Combination with ROSA ONE® Product Development/Commercial a un ▪ L ch: FDA 510K for 24 hr. use; fir
Slide 7: Development and Distribution Agreement with Zimmer Biomet
7 ▪ Zimmer is a worldwide leader in robotic technology used in minimally invasive neurosurgeries ▪ Evo ® electrode product line complementary to Zimmer’s ROSA ONE ® Brain platform ▪ Agreement signed in July 2020, $5.5 million total paid to NeuroOne ▪ Zimmer to exclusively commercialize and distribut
Slide 8: Mayo Clinic Board Representation
8 Mayo Clinic Board Representation Mayo Clinic serves as a critical partner to NeuroOne and as a shareholder of the Company ▪ Current shareholder ▪ Mayo Clinic began testing technology in pre - clinical models and clinical research in 2015 ▪ First commercial human use of Evo ® Cortical and sEEG Elec
Slide 9: Advantages vs Ablative Lasers (Current Std. of Care)
9 Advantages vs Ablative Lasers (Current Std. of Care) ▪ One procedure for diagnostic and therapeutic expected to save time, money and to improve patient outcomes. ▪ OneRF Ablation System leverages current NeuroOne sEEG technology ▪ Received FDA 510(k) clearance in December 2023 ▪ Uses well establis
Slide 10: OneRF Ablation System
10 sEEG (Already Implanted for Diagnostics) OneRF Ablation System Capital Equipment RF Procedure Single - Use Temperature Accessory Kit R F Connection Interface
Slide 11: RF Ablation for Facial Pain
RF Ablation for Facial Pain ophthalmic trigeminal Herve ganglion aye” trigeminal \F we ——brainstem
Slide 12: OneRF Advantages for Facial Pain
12 OneRF Advantages for Facial Pain Current Market: BSX/Cosman NeuroOne’s OneRF Solution Current probes all have only one contact and can map only one area at a time; • Requiring to move the probe/ contact each time for another zone • Uncomfortable for the patient and inefficient for the surgeon One
Slide 13: Drug Delivery
13 Drug Delivery - Intended to deliver drugs/genes and record effects Pre - Delivery Record Brain Activity Drug Delivery Through Electrode Post - Delivery Recording Illustrative Only
Slide 14: Combined Dx + Tx Spinal Cord Stimulation System
14 Potential NeuroOne Advantages: ▪ Ability to place paddle electrodes percutaneously ▪ Lower power requirements = battery savings ▪ Conformable design provides enhanced tissue coverage. ▪ “Scalability” of electrodes offer greater precision of targeted stimulation area ▪ Successfully completed initi
Slide 15: Percutaneous Implantation Methods
15 Percutaneous Implantation Methods In vitro Percutaneous Implantation of a 9 mm wide Paddle Electrode 1. Insert needle 5. Retract guidewire 2. Insert guidewire and introducer 3. Advance thin - film over guidewire 4. Push thin - film through introducer 6. Retract introducer 7. Thin - film deployed
Slide 16: Management Team
16 Administration from the University of St. Thomas. Dave Rosa President and Chief Executive Officer An entrepreneur with three decades of experience in the medical device industry spanning a variety of technologies and products. In addition to CEO roles with early - stage medical device companies,
Slide 17: Financial Information as of 2/29/2024
17 Financial Information as of 2/29/2024 Financial Data NASDAQ: NMTC $1.21 Price: $0.95 - $2.00 90 - Day Price Range: 198,139 Daily Volume – 90 Day Average: $31.4 Million Market Capitalization: 25.9 Million Shares Outstanding: 23.9 Million Shares in Float: 4.9 Million (WAEP = $5.20) Warrants: 2.8 Mi
Slide 18: Value Proposition and Catalysts & Milestones
18 Value Proposition ▪ Substantial market opportunity ▪ Two FDA cleared electrodes with established reimbursement; others close to FDA submission or completion of development ▪ FDA 510k clearance for OneRF ® Ablation System December 2023 ▪ Platform technology with potential for multiple applications
Slide 19: Thank You
19 Dave Rosa Chief Executive Officer T h a n k Y o u
NeuroOne Medical Technologies — Investor Presentation (March 2024) on 6ix